> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# BlackRock Unit Reports 6.3% Passive Stake In Delcath Systems
- URL: https://www.bullished.co/blackrock-unit-reports-6-3-passive-stake-in-delcath-systems-244b435f/
- Published: 2026-10-27T20:32:57.000Z
- Updated: 2026-10-27T20:32:57.000Z
- Description: The 2.18 million-share position is held for passive purposes, with BlackRock certifying it is not aimed at influencing control.
- Author: Matteo Parrino
- Tags: SEC Filings, Industry: Not classified

BlackRock Portfolio Management holds [2,180,493 shares](https://www.sec.gov/Archives/edgar/data/0002052113/000205211326001072/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) of Delcath Systems, or 6.3% of the common stock, according to a passive ownership disclosure filed Tuesday. Delcath is an interventional oncology company focused on liver cancers, based in Queensbury, N.Y.

## Voting power and the passive label

BlackRock Portfolio Management has sole voting power over 2,018,673 of the shares, and the filing lists no shared voting power. The stake is reported as of September 30, 2026, and the filing classifies the holder as a parent or holding company.

BlackRock certified that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Delcath. The filing says it reflects holdings of certain BlackRock business units, and an [exhibit](https://www.sec.gov/Archives/edgar/data/2052113/000205211326001072/Item%5F7.txt?ref=bullished.co) lists BlackRock entities including BlackRock Fund Advisors and BlackRock Institutional Trust Company.

Various persons have the right to receive dividends or sale proceeds from the shares, the filing says, and no one person's interest is more than 5% of the outstanding common stock.

## A liver-cancer drug-device maker

Delcath's lead product, HEPZATO KIT, is FDA-approved as a drug for adults with metastatic uveal melanoma and unresectable liver metastases, and it carries a boxed warning, the company said. In Europe the device-only version is sold as the CHEMOSAT Hepatic Delivery System, regulated as a Class III medical device.

Delcath shares closed at $14.75 in Tuesday trading, giving the company a market value of $503 million.

## Earnings call set for November 9

Delcath will [host a third-quarter earnings call](https://www.businesswire.com/news/home/20261026638121/en/Delcath-Systems-to-Host-Third-Quarter-2026-Earnings-Call?ref=bullished.co) on Monday, November 9, at 8:30 a.m. Eastern. Management is also slated to [appear at the UBS Global Healthcare Conference](https://finance.yahoo.com/healthcare/articles/delcath-systems-participate-upcoming-investor-123000840.html?ref=bullished.co) on November 10.

Management's next public turn comes November 9, when Delcath reports third-quarter results on its call.

### Sources

- [SCHEDULE 13G — BlackRock Portfolio Management LLC re: DELCATH SYS INC (DCTH)](https://www.sec.gov/Archives/edgar/data/0002052113/000205211326001072/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G Exhibit 99 — EXHIBIT 99: ITEM 7](https://www.sec.gov/Archives/edgar/data/2052113/000205211326001072/Item%5F7.txt?ref=bullished.co) — SEC EDGAR
- [Delcath Systems to Participate in Upcoming Investor Conferences](https://finance.yahoo.com/healthcare/articles/delcath-systems-participate-upcoming-investor-123000840.html?ref=bullished.co) — Yahoo Finance
- [Delcath Systems to Host Third Quarter 2026 Earnings Call](https://www.businesswire.com/news/home/20261026638121/en/Delcath-Systems-to-Host-Third-Quarter-2026-Earnings-Call?ref=bullished.co) — businesswire.com